About: Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis
Creator	Bhaskaran, Krishnan Smeeth, Liam Quint, Jennifer Brown, Jeremy Evans, David Douglas, Ian Bates, Chris Mathur, Rohini Mcdonald, Helen Parry, John Tomlinson, Laurie Wong, Angel Bacon, Seb Cockburn, Jonathan Collaborative, Croker, Richard Curtis, Helen Evans, Stephen Forbes, Harriet Goldacre, Ben Harper, Sam Hester, Frank Inglesby, Peter Mackenna, Brian Mehrkar, Amir Morton, Caroline Rentsch, Christopher Schultze, Anna The, Opensafely Walker, Alex Williamson, Elizabeth Hulme, William Drysdale, Henry Wing, Kevin
Source	MedRxiv
abstract	Background: Early descriptions of the coronavirus outbreak showed a lower prevalence of asthma and COPD than was expected for people diagnosed with COVID-19, leading to speculation that inhaled corticosteroids (ICS) may protect against infection with SARS-CoV-2, and development of serious sequelae. We evaluated the association between ICS and COVID-19 related death using linked electronic health records in the UK. Methods: We conducted cohort studies on two groups of people (COPD and asthma) using the OpenSAFELY platform to analyse data from primary care practices linked to national death registrations. People receiving an ICS were compared to those receiving alternative respiratory medications. Our primary outcome was COVID-19 related death. Findings: We identified 148,588 people with COPD and 817,973 people with asthma receiving relevant respiratory medications in the four months prior to 01 March 2020. People with COPD receiving ICS were at a greater risk of COVID-19 related death compared to those receiving a long-acting beta agonist (LABA) and a long-acting muscarinic antagonist (LAMA) (adjusted HR = 1.38, 95% CI = 1.08 - 1.75). People with asthma receiving high dose ICS were at an increased risk of death compared to those receiving a short-acting beta agonist (SABA) only (adjusted HR = 1.52, 95%CI = 1.08 - 2.14); the adjusted HR for those receiving low-medium dose ICS was 1.10 (95% CI = 0.82 - 1.49). Quantitative bias analyses indicated that an unmeasured confounder of only moderate strength of association with exposure and outcome could explain the observed associations in both populations. Interpretation: These results do not support a major role of ICS in protecting against COVID-19 related deaths. Observed increased risks of COVID-19 related death among people with COPD and asthma receiving ICS can be plausibly explained by unmeasured confounding due to disease severity.
has issue date	2020-06-20(xsd:dateTime)
bibo:doi	10.1101/2020.06.19.20135491
has license	medrxiv
sha1sum (hex)	1806c59873b5b79e87ab45421bbec13533b22ca9
schema:url	https://doi.org/10.1101/2020.06.19.20135491
resource representing a document's title	Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis
resource representing a document's body	covid:1806c59873b5b79e87ab45421bbec13533b22ca9#body_text
is schema:about of	named entity 'EVALUATED' named entity 'LEADING' named entity 'SARS-COV-2' named entity 'COPD' covid:arg/1806c59873b5b79e87ab45421bbec13533b22ca9 named entity 'prevalence' named entity 'coronavirus outbreak' named entity 'COVID' named entity 'asthma' named entity 'asthma' named entity 'Post-hoc analyses' named entity 'COVID-19' named entity 'COPD' named entity 'COVID-19' named entity 'COPD' named entity 'COVID' named entity 'Cox regression models' named entity 'cohort studies' named entity 'COPD' named entity 'medRxiv' named entity 'markers of disease' named entity 'COPD' named entity 'COPD' named entity 'asthma' named entity 'heterogeneity' named entity 'medRxiv' named entity 'EHR' named entity 'COVID' named entity 'confidence intervals' named entity 'human coronavirus' named entity 'treatment groups' named entity 'treatment groups' named entity 'asthma' named entity 'systematic review' named entity 'COVID' named entity 'respiratory conditions' named entity 'global health emergency' named entity 'steroid' named entity 'asthma exacerbation' named entity 'confounding' named entity 'medical records' named entity 'asthma' named entity 'respiratory disease' named entity 'asthma' named entity 'confounding' named entity 'observational studies' named entity 'confounding' named entity 'medRxiv' named entity 'medRxiv' named entity 'EHR' named entity 'medRxiv' named entity 'Post-hoc analyses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software